Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 17 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Respiratory syncytial virus vaccine (Primary)
Indications Respiratory syncytial virus infections
Focus Registrational; Therapeutic Use
Acronyms PEARL
Sponsors Sanofi Pasteur

Most Recent Events

14 Jan 2025 Status changed from recruiting to active, no longer recruiting.
27 Sep 2024 Planned End Date changed from 2 Jun 2026 to 7 Dec 2027.
15 Mar 2024 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight